Brokers Set Expectations for TSE:HLS Q1 Earnings

HLS Therapeutics Inc. (TSE:HLS) – Equities researchers at Stifel Canada issued their Q1 2025 earnings per share estimates for shares of HLS Therapeutics in a note issued to investors on Tuesday, March 25th. Stifel Canada analyst J. Keywood anticipates that the company will earn ($0.16) per share for the quarter. The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.43) EPS.

Separately, Stifel Nicolaus raised their target price on shares of HLS Therapeutics from C$3.50 to C$4.00 and gave the company a “hold” rating in a report on Wednesday.

HLS Therapeutics Stock Up 2.6 %

HLS opened at C$4.42 on Thursday. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56. The company has a market cap of C$98.33 million, a price-to-earnings ratio of -4.43 and a beta of 1.07. HLS Therapeutics has a one year low of C$3.00 and a one year high of C$5.48. The business’s fifty day moving average is C$4.17 and its two-hundred day moving average is C$3.80.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.